Treatment Outcome with Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed and Relapsed/Refractory Multiple Myeloma


Treatment Outcome with Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Slides from presentations at ASCO 2013/EHA 2013 and transcribed comments from recent interviews with Antonio Palumbo, MD (8/20/13) and Andrzej J Jakubowiak, MD, PhD (8/28/13)
Jakubowiak AJ et al. Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. Proc ASCO 2013;Abstract 8543.

Wang M et al. Final results from the Phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. Proc ASCO 2013;Abstract 8529.

Niesvizky R et al. Final results from the Phase 1b/2 study (PX-171-006) of carfilzomib in combination with lenalidomide and low-dose dexamethasone (CRd) for patients with relapsed or progressive multiple myeloma. Proc EHA 2013;Abstract S577.

Dr Palumbo is Chief of the Myeloma Unit in the University of Torino’s Division of Hematology in Torino, Italy.

Dr Jakubowiak is Professor of Medicine and Director of the Myeloma Program at The University of Chicago in Chicago, Illinois.